论文部分内容阅读
目的观察碘-131(131I)在治疗Graves病合并重症肝损害的应用效果。方法回顾性分析解放军第一八四医院收治的50例使用131I治疗Graves病进合并重症肝损害患者的临床资料,对患者治疗前后的临床症状及体征进行观察记录,比较治疗前后的肝功能指标及甲状腺激素水平。结果与治疗前相比,治疗后3个月、6个月谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总胆红素(TB)以及游离三碘甲状原氨酸(FT3)和游离甲状腺素(FT4)水平均有明显改善,差异有统计学意义(P<0.01);治疗6个月后与治疗3个月后相比,患者上述肝功能指标及甲状腺激素水平差异有统计学意义(P<0.01)。结论131I治疗Graves病合并重症肝损害效果较好,值得推广应用。
Objective To observe the effect of iodine-131 (131I) in the treatment of Graves’ disease complicated with severe liver damage. Methods The clinical data of 50 patients with 131I treated with Graves disease and severe liver damage admitted to the 184th Hospital of PLA were retrospectively analyzed. The clinical symptoms and signs before and after treatment were observed and recorded, and the liver function indexes before and after treatment were compared Thyroid hormone levels. Results Compared with those before treatment, ALT, AST, TBP and free triiodothyronine were significantly higher at 3 and 6 months after treatment (FT3) and free thyroxine (FT4) levels were significantly improved, the difference was statistically significant (P <0.01); 6 months after treatment compared with 3 months after treatment, the patient’s liver function indicators and thyroid The difference of hormone level was statistically significant (P <0.01). Conclusion 131I treatment of Graves disease with severe liver damage better, it is worth promoting the application.